Rabeprazole in GERD and Nocturnal Reflux Management - Dr G. Manoharan

Gastroesophageal reflux disease (GERD) is a common condition globally. The severity of GERD largely depends on the extent and duration of esophageal exposure to gastric acid. The primary goal of pharmacological management is to suppress gastric acid secretion, thereby reducing esophageal acid exposure. However, nocturnal acid breakthrough (NAB), characterized by a sustained drop in intra-gastric pH below 4 for over 60 minutes during the night, occurs in 40% to 70% of GERD patients despite being on proton pump inhibitors (PPIs). Rabeprazole is a proton pump inhibitor used for the treatment of acid-peptic-related disorders (gastroesophageal reflux disease [GERD], duodenal ulcer, gastric ulcer, gastric acid hypersecretory syndromes) and Helicobacter pylori.

In this video, Dr. G. Manoharan, a Gastroenterologist and Gastrointestinal specialist from Chennai with over 38 years of experience, shares his clinical insights on the use of Rabeprazole for GERD and nocturnal acid reflux.

Key questions discussed are:

1. The advantages of Rabeprazole over other commonly used PPIs, such as Pantoprazole, in terms of efficacy and safety for GERD patients.

2. Clinical benefits of Rabeprazole in treating and maintaining acid peptic diseases.

3. The role of Rabeprazole in managing nocturnal acid reflux.